Hutchison China MediTech Ltd's lung cancer drug savolitinib in combination with AstraZeneca PLC's Tagrisso or Iressa showed preliminary anti-tumor activity in two phase 1b/2 trials on patients whose disease had progressed after a first-line treatment.
The proof-of-concept trials, called TATTON, were conducted on patients with mutation-positive epidermal growth factor receptor non-small cell lung cancer who carry a mutated MET gene.
The common adverse events included nausea and vomiting, among other things, which were consistent with the known safety profiles of each of the three drugs.
Savolitinib is being studied in multiple tumor types worldwide, including kidney, lung and gastric cancers, as a monotherapy and in combination with other targeted and immunotherapy agents.
"MET-amplification impacts a meaningful proportion of patients with EGFRm NSCLC who experience disease progression following treatment with a tyrosine kinase inhibitor in the first or second-line setting. Among patients with this difficult-to-treat resistance mechanism, there is a clear unmet medical need," CEO Christian Hogg said.